Adolor (ADLR) Provides Update on Entereg(R) (alvimopan) OBD Program
More News related to ADLR
- Adolor Appoints John M. Limongelli as Senior Vice President, General Counsel and Secretary
- Brean Murray Ugprades Adolor Corp. (ADLR) to Buy
- Piper Jaffray Downgrades (ADLR) to Neutral
- Adolor Regains Rights to Entereg(R) (alvimopan) for OBD
- Brean Murray Downgrades Adolor (ADLR) to Hold
More News related to GSK
- LF Elimination Program Treats Over Half Billion People and Protects Millions More From Debilitating Disease
- GlaxoSmithKline (GSK) volatility Elevated at 43; shares near four-year low
- SAFE-BioPharma Announces Fast, Innovative Identity Proofing Procedure
- GlaxoSmithKline Named a 2008 100 Best Company by Working Mother Magazine
- alli(TM) Partners with Breast Cancer Network of Strength(TM) to Support Women Challenged by Breast Cancer, Weight Loss or Both
More News related to Corporate News
- Constar International (CNST) Announces Four-Year Agreement with Pepsi (PEP); Undertakes Restructuring Plan
- SandRidge Energy (SD) Acquires Additional Interests and Terminates Executive Well Participation Plan
- Range Resources (RRC) Reports Record Production, 19% YoY Increase
- Oracle (ORCL) CEO Says May Take Advantage of Slowing Economy to Buy Other Companies -WSJ
- Lehman CDS Auction Sets Price of 8.625c on Bonds; Sellers of Swaps Would Pay 91.375c on the Dollar
Adolor Corporation (Nasdaq: ADLR) issued an update on the Entereg(R) (alvimopan) Program for chronic opioid bowel dysfunction (OBD), under development in collaboration with GlaxoSmithKline (NYSE: GSK).
The U. S. Food and Drug Administration (FDA) has concluded that clinical investigations relating to alvimopan in OBD may now proceed, and has therefore lifted the clinical hold on the OBD Investigational New Drug Application.
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.21
-0.33Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
